BioCentury | May 19, 2020
Product Development

May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV

ChemoCentryx therapy fails Phase II study in rare renal disorder  ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study...
BC Extra | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

Biotech indexes rose as much as 33% in 2019 despite gaining little value overall in the year’s first nine months, with a series of clinical catalysts and strong appetite for M&A and licensing deals fueling...
BC Extra | Nov 26, 2019
Clinical News

ChemoCentryx's valuation reaches nearly $1.8 billion after vasculitis readout

ChemoCentryx became the latest biotech to post a triple-digit percentage gain based on a clinical readout, adding more than $1.3 billion in market cap after its avacopan showed statistical superiority to standard-of-care therapy in a...
BC Extra | Nov 26, 2019
Company News

Nov. 25 Company Quick Takes: FDA approves GBT's sickle cell therapy; plus ChemoCentryx, Astellas, La Jolla, Sorrento, Aquestive

GBT's sickle cell therapy snags accelerated approval  FDA granted accelerated approval to Oxbryta voxelotor from Global Blood Therapeutics Inc. (NASDAQ:GBT) to treat sickle cell disease three months ahead of its Feb. 26 PDUFA date, marking...
BioCentury | Jun 29, 2019

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

After reporting a high clinical response rate in a Phase IIa study, InflaRx lost $34.28 (92%) to $3.01 in afternoon trading Wednesday after all doses of IFX-1 failed to meet the primary endpoint in the...
BC Week In Review | Jan 25, 2019
Clinical News

ChemoCentryx, Vifor Fresenius to seek full approval of avacopan next year

ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma Ltd. voluntarily withdrew a conditional marketing authorization (CMA) application in the EU for avacopan (CCX168) to treat antineutrophil cytoplasmic antibody associated vasculitis, since Phase...
BC Extra | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
BC Week In Review | Jun 15, 2018
Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
Items per page:
1 - 10 of 196